Chief Customer Officer Lidia Rodriguez-Hupp on the importance of people skills and how Sentry’s 340B customers benefit from being part of The Craneware Group.
/ by Lisa Scholz, PharmD, MBA, FACHE, Senior Vice President Industry Relations
With more contract pharmacy court rulings, CMS’ proposed remedy for Medicare Part B underpayments, and increased scrutiny from Congress, 2023 promises to be a big year for the 340B program.
/ by Lisa Scholz, PharmD, MBA, FACHE, Senior Vice President Industry Relations
With more contract pharmacy court rulings, CMS’ proposed remedy for Medicare Part B underpayments, and increased scrutiny from Congress, 2023 promises to be a big year for the 340B program.
/ by Lisa Scholz, PharmD, MBA, FACHE, Senior Vice President Industry Relations
With more contract pharmacy court rulings, CMS’ proposed remedy for Medicare Part B underpayments, and increased scrutiny from Congress, 2023 promises to be a big year for the 340B program.
/ by Lisa Scholz, PharmD, MBA, FACHE, Senior Vice President Industry Relations
Covered entities can expect scrutiny from Congress, more contract pharmacy restrictions from drugmakers, appeals court rulings, and a Part B payment remedy.
Gonzalez is The Craneware Group’s new 340B training manager. He oversees all customer training offerings available through the Sentry Success Community.
/ by Lisa Scholz, PharmD, MBA, FACHE, Senior Vice President Industry Relations
Sentry, now The Craneware Group, has a new survey for customers as part of their regular meetings with their account executives, part of our commitment to excellent customer experience.
/ by Lisa Scholz, PharmD, MBA, FACHE, Senior Vice President Industry Relations
With more contract pharmacy court rulings, CMS’ proposed remedy for Medicare Part B underpayments, and increased scrutiny from Congress, 2023 promises to be a big year for the 340B program.
/ by Lisa Scholz, PharmD, MBA, FACHE, Senior Vice President Industry Relations
The November 8 midterm election left us with divided government and mixed prospects for 340B in 2023. We can expect hearings and legislation calling for greater reporting and transparency.
/ by Lisa Scholz, PharmD, MBA, FACHE, Senior Vice President Industry Relations
When Medicare begins negotiating lower drug prices, the 340B discounts will likely decrease. Covered entities will also have to exclude 340B claims from Part D.